You are here
Randomized phase III trial exploring the use of long-acting release octreotide in the prevention of chemotherapy-induced diarrhea in patients with colorectal cancer: the LARCID trial
Hoff PM, Saragiotto DF, Barrios CH, del Giglio A, Coutinho AK, Andrade AC, Dutra C, Forones NM, Correa M, Portella Mdo S, Passos VQ, Chinen RN, van Eyll B.
J Clin Oncol. 2014 Apr 1;32(10):1006-11
Editors’ comments: Dr Ricardo Caponero
Chemotherapy-induced diarrhea is a relatively common adverse event in the treatment of patients with colorectal cancer. The Long-Acting Release Octreotide for Chemotherapy-Induced Diarrhea (LARCID) trial does not prove the efficacy of octreotide LAR in the prevention of CID.